...
首页> 外文期刊>Current Pharmaceutical Biotechnology >Current Immunotherapy of Multiple Sclerosis and Future Challenges: Relevance of Immune-Mediated Repair
【24h】

Current Immunotherapy of Multiple Sclerosis and Future Challenges: Relevance of Immune-Mediated Repair

机译:多发性硬化症的当前免疫治疗和未来的挑战:免疫介导的修复的相关性。

获取原文
获取原文并翻译 | 示例

摘要

Multiple sclerosis is the most common chronic inflammatory disease of the central nervous system and can cause severe neurological disability. Current immune therapy with beta-interferons, glatiramer acetate, immune suppres-sives, or selective adhesion molecule inhibitors can reduce the frequency and severity of acute attacks in a majority of patients but have little effect on the progressive phase of the disease. Patients who require aggressive immune therapy are also at risk for the development of potentially fatal opportunistic infections. Here current and emerging immune therapy options are discussed, and immune-mediated strategies to preserve normal immune surveillance and mediate tissue repair are proposed.
机译:多发性硬化症是中枢神经系统最常见的慢性炎症性疾病,可导致严重的神经功能障碍。目前使用β-干扰素,醋酸格拉替雷,免疫抑制剂或选择性黏附分子抑制剂的免疫疗法可以降低大多数患者急性发作的频率和严重程度,但对疾病的进展期影响不大。需要积极免疫疗法的患者也有发展潜在致命机会性感染的风险。在这里讨论了当前和新兴的免疫疗法选择,并提出了免疫介导的策略来保持正常的免疫监视和介导组织修复。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号